DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Neuroimaging of Dystonia

Information source: University of Florida
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Primary Cervical Dystonia; DYT 1 Dystonia

Intervention: Primary Cervical Dystonia (Trihexyphenidyl) (Drug); Controls Primary Cervical Dystonia (Trihexyphenidyl) (Other); DYT 1 Dystonia (Healthy Control) (Other); DYT 1 Dystonia (Other)

Phase: N/A

Status: Recruiting

Sponsored by: University of Florida

Official(s) and/or principal investigator(s):
David Vaillancourt, PhD, Principal Investigator, Affiliation: University of Florida
Michael Okun, MD, Principal Investigator, Affiliation: University of Florida

Overall contact:
Erin Monari, PhD, Phone: 352-294-5030, Email: erin.hastings@neurology.ufl.edu

Summary

The main purpose of this study is to investigate primary cervical dystonia as compared to healthy control subjects and DYT 1 dystonia as compared to healthy control subjects by examining cognitive measures, physical measures, and structural and functional magnetic resonance imaging (MRI). The secondary aim of this study is to investigate a specific drug therapy for primary cervical dystonia to develop a functional MRI (fMRI) research paradigm. The drug, trihexyphenidyl, is FDA approved to treat Parkinson's Disease and is commonly prescribed by physicians as a treatment for symptoms of primary cervical dystonia.

Clinical Details

Official title: Neuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of Florida

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome:

Change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task

Change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task

Detailed description: To participate in this study, you will be asked to come to the University of Florida for one testing day. For your convenience, arrangements will be made by the study coordinator. If you have a movement disorder, you will be tested in an "off" medication condition. We do not expect concerns or unwanted consequences arising from discontinuing medications for this duration. We will review the informed consent and you will have the opportunity to ask questions before signing the informed consent. During the experiment, you may be asked to complete the following: (1) questionnaires about quality of life and depression; (2) tests to measure your strength and motor function; (3) tests to measure your cognition; (4) functional and structural MRI scan of your brain while performing a precision gripping task; (5) intravenous blood draw; (6) urine pregnancy test (if applicable); (7) trial of

anticholinergic therapy drug trihexyphenidyl (if applicable - cervical dystonia only).

Participants with DYT 1 dystonia and healthy controls are not eligible to receive the trial drug. All women of childbearing potential will be given a urine pregnancy test. The questionnaire about depression will not be given to subjects under the age of 18. If you have any metal in your eye or eyes, the researchers may require additional screening to ensure that it is safe for you to enter the MRI environment. If additional screening is determined to be necessary, you will be referred to Radiology at Shands UF for an orbitofrontal x-ray. Blood will be collected for all subjects, including healthy control subjects. The blood may be analyzed, at the University of Florida, to assess potential biomarkers for cervical dystonia and DYT 1 dystonia. Biomarker testing is another way to say genetic testing.

Eligibility

Minimum age: 7 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of primary cervical dystonia and between the ages of 18-70, OR

- Diagnosis of DYT 1 dystonia and between the ages of 7-50, OR

- Healthy control and between the ages of 7-70

Exclusion Criteria:

- Neurological impairment from: seizure disorders, stroke, hypertension, heart disease,

diabetes, traumatic brain injury (TBI), drug abuse, nerve disorders, dementia, Parkinson's Disease, dementia

- Not a candidate for magnetic resonance imaging (MRI)

- Deep brain stimulation (DBS) surgery

- Any implanted electrical device

- Pregnant or planning pregnancy

- Breastfeeding

- Claustrophobia

Locations and Contacts

Erin Monari, PhD, Phone: 352-294-5030, Email: erin.hastings@neurology.ufl.edu

University of Florida, Gainesville, Florida 32607, United States; Recruiting
David Vaillancourt, PhD, Principal Investigator
Michael Okun, MD, Principal Investigator
Additional Information

Bachmann-Strauss Dystonia & Parkinson Foundation, Inc.

Tyler's Hope for a Dystonia Cure

UF Center for Movement Disorders & Neurorestoration

Starting date: May 2014
Last updated: June 1, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017